Aster DM Healthcare has reported a post-tax profit of ₹106 crore for the quarter ending March 31, up 21% from ₹87 crore in the same period last year. The company's revenue for the fourth quarter of financial year 2025 stood at ₹1,000 crore—just about 2% higher than the previous year.
While the revenue growth appears modest, operational performance tells a different story. The operating EBITDA—a measure of profitability before interest, taxes, and other non-core costs—rose 16% to ₹193 crore.
For the full financial year ending March 2025, Aster clocked in total revenue of ₹4,138 crore, marking a 12% jump compared to last year. Operating EBITDA for the year stood at ₹806 crore, a sharp 30% increase from the previous period.
The company has confirmed that its planned merger with Quality Care India Limited is moving forward. Backed by Blackstone, Quality Care runs a network of hospitals across major Indian cities under names such as Care Hospitals, KIMS Health, and Evercare. The group reportedly operates 26 healthcare centres across 14 cities, with over 5,150 beds.
Aster has added 300 beds over the past year, pushing its total to 5,159. If all goes as planned, another 2,100 beds could be added, taking the total to around 7,300 in the near future.
Aster’s chairman Dr Azad Moopen said the company’s fourth-quarter performance reflected its focus on operational efficiency and patient care. He also suggested the merger could significantly enhance Aster’s reach and capabilities in India.
During the quarter, Aster also introduced a couple of firsts. The hospital chain rolled out India’s first intra-operative electron radiation therapy (IOeRT) programme—an advanced form of cancer treatment delivered during surgery.
Additionally, it launched the Aster Health app across its hospitals to help patients manage their care more easily.
Despite the steady numbers, the stock didn't quite cheer investors. On May 21, Aster DM Healthcare shares fell 3.72%, trading at ₹557.85 on the BSE.
While the merger could reshape Aster’s position in the Indian healthcare space, investors and observers might be waiting to see how it all plays out.